| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2983196 | The Journal of Thoracic and Cardiovascular Surgery | 2007 | 7 Pages |
Abstract
The range of properties displayed by NCX 4016 (inhibition of neointima formation, gastroprotection, antithrombotic and antiatherogenic effects) renders them potentially useful in treating both early and late vein graft failure and indicates that a clinical study on this novel drug class in patients undergoing coronary bypass grafting is warranted.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Song FRCS, Nilima PhD, Gianni D. FRCS, Anthony P.C. FRCS, Jason L. PhD, Jamie Y. PhD,